Effects of soy isoflavone on hepatic steatosis in high fat-induced rats

Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huanhuan, Zhong, Huijia, Leng, Liang, Jiang, Zhuoqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612816/
https://www.ncbi.nlm.nih.gov/pubmed/28955124
http://dx.doi.org/10.3164/jcbn.16-98
_version_ 1783266131785547776
author Liu, Huanhuan
Zhong, Huijia
Leng, Liang
Jiang, Zhuoqin
author_facet Liu, Huanhuan
Zhong, Huijia
Leng, Liang
Jiang, Zhuoqin
author_sort Liu, Huanhuan
collection PubMed
description Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were administrated with a normal fat diet (control), HFD (NAFLD model), HFD with 10 or 20 mg/kg soy isoflavone daily for 12 weeks. Hepatic and serum lipid contents, liver histopathological examination, serum alanine transaminase (ALT), protein and mRNA expression of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), peroxisome proliferator-activated receptor (PPAR) α were assayed respectively. Our study found that soy isoflavone reduced HFD-induced lipid accumulation in liver, serum ALT and improved liver lobule structure. In addition, the expression of SREBP-1c and FAS was lower, whereas protein level of PPARα was higher in two soy isoflavone groups than that of the HFD group. Collectively, these results demonstrate that soy isoflavone is capable of alleviating hepatic steatosis and delaying the progression of NAFLD via inhibiting lipogenesis and promoting fatty acid oxidation in liver.
format Online
Article
Text
id pubmed-5612816
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-56128162017-09-27 Effects of soy isoflavone on hepatic steatosis in high fat-induced rats Liu, Huanhuan Zhong, Huijia Leng, Liang Jiang, Zhuoqin J Clin Biochem Nutr Original Article Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were administrated with a normal fat diet (control), HFD (NAFLD model), HFD with 10 or 20 mg/kg soy isoflavone daily for 12 weeks. Hepatic and serum lipid contents, liver histopathological examination, serum alanine transaminase (ALT), protein and mRNA expression of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), peroxisome proliferator-activated receptor (PPAR) α were assayed respectively. Our study found that soy isoflavone reduced HFD-induced lipid accumulation in liver, serum ALT and improved liver lobule structure. In addition, the expression of SREBP-1c and FAS was lower, whereas protein level of PPARα was higher in two soy isoflavone groups than that of the HFD group. Collectively, these results demonstrate that soy isoflavone is capable of alleviating hepatic steatosis and delaying the progression of NAFLD via inhibiting lipogenesis and promoting fatty acid oxidation in liver. the Society for Free Radical Research Japan 2017-09 2017-07-20 /pmc/articles/PMC5612816/ /pubmed/28955124 http://dx.doi.org/10.3164/jcbn.16-98 Text en Copyright © 2017 JCBN http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Liu, Huanhuan
Zhong, Huijia
Leng, Liang
Jiang, Zhuoqin
Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title_full Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title_fullStr Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title_full_unstemmed Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title_short Effects of soy isoflavone on hepatic steatosis in high fat-induced rats
title_sort effects of soy isoflavone on hepatic steatosis in high fat-induced rats
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612816/
https://www.ncbi.nlm.nih.gov/pubmed/28955124
http://dx.doi.org/10.3164/jcbn.16-98
work_keys_str_mv AT liuhuanhuan effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats
AT zhonghuijia effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats
AT lengliang effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats
AT jiangzhuoqin effectsofsoyisoflavoneonhepaticsteatosisinhighfatinducedrats